Indeed, promoter hypermethylation of TMEM88 is associated with poorer prognosis of non-small cell lung cancer (Ma et al., 2017), whereas the hypomethylation is associated with platinum resistance in ovarian cancer (de Leon et al., 2016). Here, TMEM88 is linked to ovarian carcinoma.